What is RNAZ's dilution risk score?

RNAZ has a latest available DilutionScore record of 89/100, categorized as critical dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for RNAZ, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for RNAZ?

DilutionWatch tracks 25 SEC filing types for RNAZ including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect RNAZ shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For RNAZ, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for RNAZ tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for RNAZ. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

RNAZ Dilution Risk Score: 89/100 (CRITICAL)

Score Breakdown

📋 Offering Ability

100

💰 Cash Runway

65

📊 Float Risk

100

⚠️ Warrant Exposure

40

🔄 Convertible Debt

60

Dilution Forecast

🌥️

Advisory

Moderate dilution signals present

model est. 33%

🔁 Convertible Conversion model 40%

• Significant convertible debt: 24% potential dilution

• Elevated convertible risk (60/100)

💰 Capital Raise model 35%

• Under 12 months cash (6mo)

• Active shelf registration ($20M, 399% of market cap)

📉 Score Deterioration model 15%

• Score already CRITICAL (89/100) — events likely imminent

🔔 Track RNAZ — Get forecast alerts →

Market Data

Market Cap$4.88M

Shares Outstanding16.93M

Float835.4K

Cash$8.38M

DebtN/A

Short InterestN/A

Institutional Holdings

8 institutional holders · 37.4K shares

#1 VANGUARD CAPITAL MANAGEMENT LLC 13.1K shares

#2 GEODE CAPITAL MANAGEMENT, LLC 12.7K shares

#3 UBS Group AG 8.3K shares

+ 5 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest28.3K

Days to Cover1.8

% of Float3.4%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2026-06-30

xbrl XBRL WARRANT 2025-12-31

S-1 SHELF 2026-05-01

S-3 SHELF 2026-04-30

8-K 8K EVENT 2026-04-07

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual RNAZ Dilution Snapshot

TransCode Therapeutics, Inc. (RNAZ) has a DilutionScore of 89/100, rated Critical dilution risk. Score date: August 28, 2026.

Stored shelf registration capacity: $19.5M.
Recent SEC activity tracked for RNAZ: xbrl on 2026-06-30; S-1 on 2026-05-01; S-3 on 2026-04-30.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.